Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
This article was originally published in PharmAsia News
Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts
You may also be interested in...
Sanofi plans to build its third manufacturing plant in Vietnam to expand exports into the Association of Southeast Asian Nations trading bloc and meet growing domestic demand. The company’s deep roots in the region via acquisitions give it an edge over other MNCs.
Invida CEO John Graham On Commercializing Products In Asia: An Interview With PharmAsia News (Part 1 of 2)
On the sidelines of the JP Morgan Healthcare Conference, Graham talks about Menarini’s acquisition of Invida, plans for expansion in China and India, and his favorite non-BRIC emerging markets.
Turkey has attracted considerable attention in recent years from multinational pharmaceutical companies looking to grow in emerging markets. But the government of the world's 12-largest pharmaceutical market has also enforced steep price cuts on drugs in each of the last two years, both times in December. With December quickly approaching, are a new round of price cuts on the horizon